deltatrials

Multiple myeloma Trials in Halle, Germany

Conditions / Multiple myeloma / Halle, Germany

Clinical trials for Multiple myeloma investigate a range of treatment strategies and patient populations.

13 total trials for this combination

Showing top 10 of 13 trials

Trials

NCT ID Title Status Phase
NCT05675319 Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy TERMINATED PHASE3
NCT06208150 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide RECRUITING PHASE3
NCT00416273 A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma COMPLETED PHASE3
NCT02654990 Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma COMPLETED PHASE2
NCT05552222 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma RECRUITING PHASE3
NCT05804032 Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma COMPLETED PHASE3
NCT00833560 A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy COMPLETED PHASE2
NCT02739594 Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma TERMINATED PHASE3
NCT00546988 Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years UNKNOWN PHASE3
NCT02145598 Treatment Optimization in Patients With Untreated Multiple Myeloma TERMINATED PHASE2/PHASE3

Related Pages